# Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Source: https://onco.cc/trials/nct04375683/  
OnCo record `nct04375683` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Flumatinib in Leukaemia, run by Zhongda Hospital, with a status the registry has not verified recently.

## Summary

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL is a phase 3 interventional study registered as NCT04375683 by Zhongda Hospital, with 28 participants planned, started 2020-03-01 and due to reach its primary completion in 2022-12-30. Interventions recorded: Flumatinib. Conditions recorded: Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression.

Linked to the drug Flumatinib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04375683
- Phase: 3
- Setting: A Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring
- Sponsor: Zhongda Hospital
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT04375683: https://clinicaltrials.gov/study/NCT04375683

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Flumatinib](https://onco.cc/drugs/flumatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct04375683.json